Skip to main content
. 2020 Jun 23;22:69. doi: 10.1186/s13058-020-01303-9

Table 2.

Association of PD-L1 staining with clinicopathologic factors in all patients with neoadjuvant chemotherapy

TC TCIC IC sTIL level
Factors Negative Positive Fisher Negative Positive Fisher Negative Positive Fisher Low High Fisher
N (%) N (%) P value N (%) N (%) P value N (%) N (%) P value N (%) N (%) P value
Age [N = 141] [N = 131] [N = 131] [N = 145]
 < 50 years 50 (94) 3 (6) 0.535 45 (88) 6 (12) 0.1651 47 (92) 4 (8) 0.1257 41 (73) 15 (27) 0.557
 ≥ 50 years 79 (90) 9 (10) 62 (78) 18 (23) 65 (81) 15 (19) 69 (78) 20 (22)
Race/ethnicity [N = 141] [N = 131] [N = 131] [N = 145]
 Black 19 (79) 5 (21) 0.0228 18 (75) 6 (25) 0.5126 20 (83) 4 (17) 0.9225 16 (70) 7 (30) 0.6991
 White+Latino 97 (95) 5 (5) 78 (84) 15 (16) 80 (86) 13 (14) 82 (77) 24 (23)
 Others 13 (87) 2 (13) 11 (79) 3 (21) 12 (86) 2 (14) 12 (75) 4 (25)
Histologic type [N = 141] [N = 131] [N = 131] [N = 145]
 IDC 106 (91) 10 (9) 0.0737 85 (79) 22 (21) 0.0624 89 (83) 18 (17) 0.2508 87 (73) 33 (28) 0.1731
 ILC 17 (100) 0 (0) 16 (100) 0 (0) 16 (100) 0 (0) 16 (94) 1 (6)
 Metaplastic 3 (60) 2 (40) 3 (60) 2 (40) 4 (80) 1 (20) 4 (80) 1 (20)
 Mixed IDC/ILC 3 (100) 0 (0) 3 (100) 0 (0) 3 (100) 0 (0) 3 (100) 0 (0)
Histologic gradea [N = 141] [N = 131] [N = 131] [N = 145]
 1 + 2 68 (100) 0 (0) 0.0003 62 (95) 3 (5) 0.0001 62 (95) 3 (5) 0.0022 65 (88) 9 (12) 0.0008
 3 61 (84) 12 (16) 45 (68) 21 (32) 50 (76) 16 (24) 45 (63) 26 (37)
sTIL level [N = 139] [N = 131] [N = 131] NA
 < 10% 102 (97) 3 (3) 0.0002 89 (91) 9 (9) < 0.0001 90 (92) 8 (8) 0.0006
 ≥ 10% 25 (74) 9 (26) 16 (52) 15 (48) 20 (65) 11 (35)
ER [N = 141] [N = 131] [N = 131] [N = 145]
 Negative 30 (77) 9 (23) 0.0005 20 (57) 15 (43) < 0.0001 24 (69) 11 (31) 0.0019 22 (56) 17 (44) 0.0018
 Positive 99 (97) 3 (3) 87 (91) 9 (9) 88 (92) 8 (8) 88 (83) 18 (17)
PR [N = 141] [N = 131] [N = 131] [N = 145]
 Negative 48 (83) 10 (17) 0.0037 34 (67) 17 (33) 0.0009 39 (76) 12 (24) 0.0236 36 (62) 22 (38) 0.0026
 Positive 81 (98) 2 (2) 73 (91) 7 (9) 73 (91) 7 (9) 74 (85) 13 (15)
HER2 [N = 141] [N = 131] [N = 131] [N = 145]
 Negative 118 (91) 12 (9) 0.5987 98(81) 23 (19) 0.6881 103 (85) 18 (15) 1 99 (75) 33 (25) 0.7344
 Positive 11 (100) 0 (0) 9(90) 1 (10) 9 (90) 1 (10) 11 (85) 2 (15)
TNBC [N = 141] [N = 131] [N = 131] [N = 145]
 No 101 (97) 3 (3) 0.0003 88 (91) 9 (9) < 0.0001 89 (92) 8 (8) 0.0014 90 (83) 18 (17) 0.0007
 Yes 28 (76) 9 (24) 19 (56) 15 (44) 23 (68) 11 (32) 20 (54) 17 (46)
Receptor group [N = 141] [N = 131] [N = 131] [N = 145]
 ER/PR pos 90 (97) 3 (3) 0.0012 79 (91) 8 (9) 0.0001 80 (92) 7 (8) 0.0038 79 (83) 16 (17) 0.0023
 HER2 11 (100) 0 (0) 9 (90) 1 (10) 9 (90) 1 (10) 11 (85) 2 (15)
 TNBC 28 (76) 9 (24) 19 (56) 15 (44) 23 (68) 11 (32) 20 (54) 17 (46)
Tumor size [N = 141] [N = 131] [N = 131] [N = 145]
 ≤ 2 cm 26 (84) 5 (16) 0.2433 19 (73) 7 (27) 0.4286 20 (77) 6 (23) 0.3765 21 (62) 13 (38) 0.049
 > 2 to 5 cm 54 (93) 4 (7) 49 (84) 9 (16) 51 (88) 7 (12) 43 (75) 14 (25)
 > 5 cm 49 (94) 3 (6) 39 (83) 8 (17) 41 (87) 6 (13) 46 (85) 8 (15)
ypN [N = 141] [N = 131] [N = 131] [N = 145]
 (y)pN0 39 (85) 7 (15) 0.0921 33 (77) 10 (23) 0.6247 36 (84) 7 (16) 0.9424 35 (74) 12 (26) 0.3048
 (y)pN1 45 (96) 2 (4) 36 (84) 7 (16) 36 (84) 7 (16) 37 (74) 13 (26)
 (y)pN2 22 (88) 3 (12) 19 (79) 5 (21) 21 (88) 3 (13) 18 (69) 8 (31)
 (y)pN3 23 (100) 0 (0) 19 (90) 2 (10) 19 (90) 2 (10) 20 (91) 2 (9)
pM [N = 141] [N = 131] [N = 131] [N = 145]
 0 119 (91) 12 (9) 1 101 (82) 22 (18) 0.6382 106 (86) 17 (14) 0.3272 100 (74) 35 (26) 0.1184
 1 10 (100) 0 (0) 6 (75) 2 (25) 6 (75) 2 (25) 10 (100) 0 (0)
RCB category [N = 140] [N = 130] [N = 130] [N = 144]
 I 4 (80) 1 (20) 0.5155 3 (75) 1 (25) 0.4125 3 (75) 1 (25) 0.2473 5 (83) 1 (17) 0.9425
 II 63 (91) 6 (9) 54 (86) 9 (14) 57 (90) 6 (10) 56 (77) 17 (23)
 III 61 (92) 5 (8) 49 (78) 14 (22) 51 (81) 12 (19) 48 (74) 17 (26)

aHistologic grade for post-treatment tumors was based on pre-treatment grade

IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, sTIL stromal tumor infiltrating lymphocytes, ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, pos positive, RCB residual cancer burden